Brandee McKoon tried the traditional diets to lose weight but didn’t have much luck. The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually ...

Diabetes, particularly Type 2 Diabetes (T2DM), has been linked to an increased risk of various cancers, including liver, colorectal, and breast cancer.

A recent review examined how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may affect cancer growth.

Compared with insulin alone, oral antidiabetic drugs alone or in addition to insulin were associated with reduced fracture risks among patients with type 2 diabetes. Oral antidiabetic drugs (OADs) are ...

Common diabetes drugs may do more than regulate blood sugar—they could also influence how cancers grow, spread, or slow down.

In a recent study published in The Lancet EBioMedicine, a team of scientists used Mendelian Randomization analyses to explore whether antidiabetic medications could potentially be used as ...

Among individuals with a diagnosis of type 2 diabetes across the United States, income level, hemoglobin A1c, and comorbidity burden were the primary patient-level drivers of the use of newer ...

Researchers at Case Western Reserve School of Medicine have found that, when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of ...

A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid type 2 ...

Most newly treated patients with type 2 diabetes exhibit suboptimal medication persistence, which is associated with higher risk of hospitalization and increased medical costs. Objectives: Medication ...

What about in the real word, far away from the ideal conditions of randomized trials? Could combining SGLT2 inhibitors with GLP-1R agonists be even more effective? These are the questions answered by ...